163 related articles for article (PubMed ID: 8303299)
41. Biological activities of human tumor necrosis factor-alpha and its novel mutants.
Xi T; Shi X; Guo D; Dong X; Xu X; Zhu D
Biochem Mol Biol Int; 1996 May; 38(6):1183-9. PubMed ID: 8739040
[TBL] [Abstract][Full Text] [Related]
42. Mapping the domain(s) critical for the binding of human tumor necrosis factor-alpha to its two receptors.
Chen PC; DuBois GC; Chen MJ
J Biol Chem; 1995 Feb; 270(6):2874-8. PubMed ID: 7852363
[TBL] [Abstract][Full Text] [Related]
43. Structure-activity studies of human tumour necrosis factors.
Van Ostade X; Tavernier J; Fiers W
Protein Eng; 1994 Jan; 7(1):5-22. PubMed ID: 8140094
[TBL] [Abstract][Full Text] [Related]
44. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.
Ashkenazi A; Marsters SA; Capon DJ; Chamow SM; Figari IS; Pennica D; Goeddel DV; Palladino MA; Smith DH
Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10535-9. PubMed ID: 1660140
[TBL] [Abstract][Full Text] [Related]
45. Identification of the binding site of 55kDa tumor necrosis factor receptor by synthetic peptides.
Lie BL; Tunemoto D; Hemmi H; Mizukami Y; Fukuda H; Kikuchi H; Kato S; Numao N
Biochem Biophys Res Commun; 1992 Oct; 188(2):503-9. PubMed ID: 1332702
[TBL] [Abstract][Full Text] [Related]
46. Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity.
Rathjen DA; Ferrante A; Aston R
Immunology; 1993 Oct; 80(2):293-9. PubMed ID: 8262557
[TBL] [Abstract][Full Text] [Related]
47. Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.
Browning JL; Dougas I; Ngam-ek A; Bourdon PR; Ehrenfels BN; Miatkowski K; Zafari M; Yampaglia AM; Lawton P; Meier W
J Immunol; 1995 Jan; 154(1):33-46. PubMed ID: 7995952
[TBL] [Abstract][Full Text] [Related]
48. Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes.
Browning JL; Sizing ID; Lawton P; Bourdon PR; Rennert PD; Majeau GR; Ambrose CM; Hession C; Miatkowski K; Griffiths DA; Ngam-ek A; Meier W; Benjamin CD; Hochman PS
J Immunol; 1997 Oct; 159(7):3288-98. PubMed ID: 9317127
[TBL] [Abstract][Full Text] [Related]
49. Identification of specific sites in the TNF-alpha molecule promoting insulin resistance in H-411E cells.
Solomon SS; Mishra SK; Palazzolo MR; Postlethwaite AE; Seyer JM
J Lab Clin Med; 1997 Aug; 130(2):139-46. PubMed ID: 9280141
[TBL] [Abstract][Full Text] [Related]
50. Differences in the biological activity of TNF alpha and TNF beta correlate with their different abilities for binding to the target cells.
Kircheis R; Milleck J; Korobko VG; Shingarova LN; Schmidt HE
Eur Cytokine Netw; 1992; 3(4):381-90. PubMed ID: 1330049
[TBL] [Abstract][Full Text] [Related]
51. [Cloning and structural analysis of genes coding for tumor necrosis factor and lymphotoxin in rabbits].
Shakhov AN; Kuprash DV; Turetskaia RL; Azizov MM; Andreeva AV; Nedospasov SA
Mol Biol (Mosk); 1989; 23(6):1743-50. PubMed ID: 2633043
[TBL] [Abstract][Full Text] [Related]
52. Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs.
Rennert PD; Browning JL; Mebius R; Mackay F; Hochman PS
J Exp Med; 1996 Nov; 184(5):1999-2006. PubMed ID: 8920886
[TBL] [Abstract][Full Text] [Related]
53. Effects of tumor necrosis factor and lymphotoxin on peripheral lymphoid tissue development.
Ettinger R; Mebius R; Browning JL; Michie SA; van Tuijl S; Kraal G; van Ewijk W; McDevitt HO
Int Immunol; 1998 Jun; 10(6):727-41. PubMed ID: 9678753
[TBL] [Abstract][Full Text] [Related]
54. Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein.
Himmler A; Maurer-Fogy I; Krönke M; Scheurich P; Pfizenmaier K; Lantz M; Olsson I; Hauptmann R; Stratowa C; Adolf GR
DNA Cell Biol; 1990 Dec; 9(10):705-15. PubMed ID: 1702293
[TBL] [Abstract][Full Text] [Related]
55. Differences in the bioactivity of recombinant human TNF, LT, and T-cell-derived LT-3 on transformed cells in vitro and the Meth A tumor growing in BALB/c mice.
Granger GA; Masunaka I; Averbook B; Kobayashi M; Fitzgerald M; Yamamoto R
J Biol Response Mod; 1988 Oct; 7(5):488-97. PubMed ID: 3263472
[TBL] [Abstract][Full Text] [Related]
56. Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor.
Espevik T; Brockhaus M; Loetscher H; Nonstad U; Shalaby R
J Exp Med; 1990 Feb; 171(2):415-26. PubMed ID: 1689365
[TBL] [Abstract][Full Text] [Related]
57. Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning.
Abe Y; Yoshikawa T; Inoue M; Nomura T; Furuya T; Yamashita T; Nagano K; Nabeshi H; Yoshioka Y; Mukai Y; Nakagawa S; Kamada H; Tsutsumi Y; Tsunoda S
Biomaterials; 2011 Aug; 32(23):5498-504. PubMed ID: 21546081
[TBL] [Abstract][Full Text] [Related]
58. Mature follicular dendritic cell networks depend on expression of lymphotoxin beta receptor by radioresistant stromal cells and of lymphotoxin beta and tumor necrosis factor by B cells.
Endres R; Alimzhanov MB; Plitz T; Fütterer A; Kosco-Vilbois MH; Nedospasov SA; Rajewsky K; Pfeffer K
J Exp Med; 1999 Jan; 189(1):159-68. PubMed ID: 9874572
[TBL] [Abstract][Full Text] [Related]
59. Identification of TNF-alpha binding peptides from a D-amino acid hexapeptide library that specifically inhibit TNF-alpha binding to recombinant p55 receptor.
Kruszynski M; Shealy DJ; Leone AO; Heavner GA
Cytokine; 1999 Jan; 11(1):37-44. PubMed ID: 10080877
[TBL] [Abstract][Full Text] [Related]
60. [Defense mechanisms in trypanosomiasis].
Daulouede PS; Okomo-Assoumou MC; Labassa M; Fouquet C; Vincendeau P
Bull Soc Pathol Exot; 1994; 87(5):330-2. PubMed ID: 7496195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
